Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer â An AZURE (BIG 01/04) sub-study
Purpose: Adjuvant bisphosphonates have been shown to improve disease outcomes in early breast cancer in women who are postmenopausal at the start of treatment. We explored the influence of pretreatment serum levels of reproductive hormones in the hypothalamic-pituitary-gonadal (HPG) axis from a subs...
Main Authors: | Caroline Wilson, Samantha Hinsley, Helen Marshall, David Cameron, Richard Bell, David Dodwell, Robert E. Coleman |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-11-01
|
Series: | Journal of Bone Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137416301026 |
Similar Items
-
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
by: R.E. Coleman, et al.
Published: (2018-11-01) -
BoHFAB. The impact of adjuvant zoledronate therapy on bone health in postmenopausal patients with early breast cancer
by: Janet Brown, et al.
Published: (2024-04-01) -
Optimising trial monitoring on the AZURE trial
by: Matthews Geraldine A, et al.
Published: (2011-12-01) -
Scalable Extraction of Big Macromolecular Data in Azure Data Lake Environment
by: Dariusz Mrozek, et al.
Published: (2019-01-01) -
Azur like it /
by: Holden, Wendy, 1965-
Published: (2003)